Top

Current Oncology Reports

Published in:

01-05-2022 | Systemic Therapy | Head and Neck Cancers (EY Hanna, Section Editor)

Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma

Authors: Luana Guimaraes de Sousa, Felippe Lazar Neto, Jessica Lin, Renata Ferrarotto

Published in: Current Oncology Reports | Issue 5/2022

Abstract

Purpose of Review

Adenoid cystic carcinoma (ACC) is a rare and heterogeneous malignancy of secretory glands. Recurrence after curative-intent treatment is common, and approximately 40% of patients develop metastatic disease, for which consensus is lacking regarding therapeutic approaches. Here, we review the available therapies for recurrent/metastatic (R/M) ACC and offer our perspectives on future treatment options.

Recent Findings

Proteogenomic studies of ACC revealed two molecular subtypes with therapeutic implications: ACC-I (37% of cases) and ACC-II (63%); each has distinct disease biology and prognosis. Molecular drivers, such as NOTCH1, have emerged as potential therapeutic targets for ACC-I and are being explored in clinical trials.

Summary

Despite its biological heterogeneity, treatment for R/M ACC is not personalized and limited to cytotoxic agents and VEGFR inhibitors, which produce modest responses and significant toxicity. The increasing understanding of ACC’s molecular biology might guide the development of biomarkers for patient selection and new therapies development.

Ellington CL, Goodman M, Kono SA, Grist W, Wadsworth T, Chen AY, et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973-2007 surveillance, epidemiology, and end results data. Cancer. 2012;118(18):4444–51. https://doi.org/10.1002/cncr.27408.CrossRefPubMed

Spiro RH. Distant metastasis in adenoid cystic carcinoma of salivary origin. Am J Surg. 1997;174(5):495–8. https://doi.org/10.1016/s0002-9610(97)00153-0.CrossRefPubMed

Moskaluk CA. Adenoid cystic carcinoma: clinical and molecular features. Head Neck Pathol. 2013;7(1):17–22. https://doi.org/10.1007/s12105-013-0426-3.CrossRefPubMedPubMedCentral

West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, et al. Myb expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. The American journal of surgical pathology. 2011;35(1):92–9. https://doi.org/10.1097/PAS.0b013e3182002777.CrossRefPubMedPubMedCentral

de Almeida-Pinto YD, Costa S, de Andrade BAB, Altemani A, Vargas PA, Abreu LG, et al. T(6;9)(MYB-NFIB) in head and neck adenoid cystic carcinoma: a systematic review with meta-analysis. Oral Dis. 2019;25(5):1277–82. https://doi.org/10.1111/odi.12984.CrossRefPubMed

•• Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J et al. Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest. 2019;129(10):4276-89. doi:10.1172/jci128227. Genomic analysis of 1045 ACCs identified R/M disease is associated with higher rates of NOTCH activating mutations and suggested molecular classification for ACC based on MYB, NOTCH, and TERT status.

•• Ferrarotto R, Mitani Y, McGrail DJ, Li K, Karpinets TV, Bell D et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin Cancer Res. 2021;27(3):852-64. doi:10.1158/1078-0432.Ccr-20-1192. This study suggested two molecular subtypes of ACC tumors, ACC-I and ACC-II, through unsupervised clustering of RNA and proteomics; each subtype has distinct disease biology and prognosis.

• Morris LGT, Chandramohan R, West L, Zehir A, Chakravarty D, Pfister DG et al. The molecular landscape of recurrent and metastatic head and neck cancers: insights from a precision oncology sequencing platform. JAMA Oncol. 2017;3(2):244-55. doi:10.1001/jamaoncol.2016.1790. This study accessed the molecular landscape of ACC through next-generation sequencing. Results showed a low tumor mutational burden and activating NOTCH1 mutation in 22% cases of metastatic ACC, which can guide therapy.

Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the dutch head and neck oncology cooperative group. Head Neck. 2004;26(8):681–92; discussion 92-3. https://doi.org/10.1002/hed.10400.CrossRefPubMed

10.

Jang S, Patel PN, Kimple RJ, McCulloch TM. Clinical outcomes and prognostic factors of adenoid cystic carcinoma of the head and neck. Anticancer Res. 2017;37(6):3045-52. doi:10.21873/anticanres.11659.

11.

Chen AM, Garcia J, Bucci MK, Chan AS, Kaplan MJ, Singer MI, et al. Recurrent salivary gland carcinomas treated by surgery with or without intraoperative radiation therapy. Head Neck. 2008;30(1):2–9. https://doi.org/10.1002/hed.20651.CrossRefPubMed

12.

Spiro RH, Huvos AG. Stage means more than grade in adenoid cystic carcinoma. Am J Surg. 1992;164(6):623–8. https://doi.org/10.1016/s0002-9610(05)80721-4.CrossRefPubMed

13.

He S, Li P, Zhong Q, Hou L, Yu Z, Huang Z, et al. Clinicopathologic and prognostic factors in adenoid cystic carcinoma of head and neck minor salivary glands: a clinical analysis of 130 cases. Am J Otolaryngol. 2017;38(2):157–62. https://doi.org/10.1016/j.amjoto.2016.11.014.CrossRefPubMed

14.

Mücke T, Tannapfel A, Kesting MR, Wagenpfeil S, Robitzky LK, Wolff K-D, et al. Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx. 2010;37(5):615–20. https://doi.org/10.1016/j.anl.2010.02.001.CrossRefPubMed

15.

Nisa L, Borner U, Dür C, Arnold A, Giger R. Recurrent parotid gland carcinoma: how effective is salvage surgery? Eur Arch Otorhinolaryngol. 2018;275(2):507–13. https://doi.org/10.1007/s00405-017-4829-8.CrossRefPubMed

16.

Kobayashi K, Nakao K, Yoshida M, Ando M, Ebihara Y, Asakage T, et al. Recurrent cancer of the parotid gland: how well does salvage surgery work for locoregional failure? ORL J Otorhinolaryngol Relat Spec. 2009;71(5):239–43. https://doi.org/10.1159/000236013.CrossRefPubMed

17.

Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck. 2003;25(11):953–9. https://doi.org/10.1002/hed.10310.CrossRefPubMed

18.

Pfister DG, Spencer S, Adelstein D, Adkins D, Anzai Y, Brizel DM, et al. Head and neck cancers, version 2.2020, nccn clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873–98. https://doi.org/10.6004/jnccn.2020.0031.CrossRefPubMed

19.

Barnett TA, Kapp DS, Goffinet DR. Adenoid cystic carcinoma of the salivary glands. Management of recurrent, advanced, or persistent disease with hyperthermia and radiation therapy. Cancer. 1990;65(12):2648–56. https://doi.org/10.1002/1097-0142(19900615)65:12<2648::aid-cncr2820651209>3.0.co;2-0.CrossRefPubMed

20.

Pederson AW, Haraf DJ, Blair EA, Stenson KM, Witt ME, Vokes EE, et al. Chemoreirradiation for recurrent salivary gland malignancies. Radiother Oncol. 2010;95(3):308–11. https://doi.org/10.1016/j.radonc.2010.03.006.CrossRefPubMed

21.

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52. https://doi.org/10.1056/NEJMoa032641.CrossRefPubMed

22.

Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44. https://doi.org/10.1056/NEJMoa032646.CrossRefPubMed

23.

Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, et al. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;84(5):1198–205. https://doi.org/10.1016/j.ijrobp.2012.05.008.CrossRefPubMedPubMedCentral

24.

Kokemueller H, Eckardt A, Brachvogel P, Hausamen JE. Adenoid cystic carcinoma of the head and neck--a 20 years experience. Int J Oral Maxillofac Surg. 2004;33(1):25–31. https://doi.org/10.1054/ijom.2003.0448.CrossRefPubMed

25.

Locati LD, Guzzo M, Bossi P, Massone PPB, Conti B, Fumagalli E, et al. Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland. Oral Oncol. 2005;41(9):890–4. https://doi.org/10.1016/j.oraloncology.2005.04.014.CrossRefPubMed

26.

Bobbio A, Copelli C, Ampollini L, Bianchi B, Carbognani P, Bettati S, et al. Lung metastasis resection of adenoid cystic carcinoma of salivary glands. Eur J Cardiothorac Surg. 2008;33(5):790–3. https://doi.org/10.1016/j.ejcts.2007.12.057.CrossRefPubMed

27.

Girelli L, Locati L, Galeone C, Scanagatta P, Duranti L, Licitra L, et al. Lung metastasectomy in adenoid cystic cancer: is it worth it? Oral Oncol. 2017;65:114–8. https://doi.org/10.1016/j.oraloncology.2016.10.018.CrossRefPubMed

28.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–59. https://doi.org/10.6004/jnccn.2021.0012.CrossRefPubMed

29.

Palma DA, Louie AV, Rodrigues GB. New strategies in stereotactic radiotherapy for oligometastases. Clin Cancer Res. 2015;21(23):5198–204. https://doi.org/10.1158/1078-0432.Ccr-15-0822.CrossRefPubMed

30.

Lehrer EJ, Singh R, Wang M, Chinchilli VM, Trifiletti DM, Ost P, et al. Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis. JAMA Oncology. 2021;7(1):92–106. https://doi.org/10.1001/jamaoncol.2020.6146.CrossRefPubMed

31.

Kobayashi D, Abe T, Saitoh J-I, Oike T, Sato H, Musha A et al. Stereotactic body radiotherapy for adenoid cystic carcinoma metastatic to the lung: a case report. J Med Case Reports. 2021;15(1):156. doi:10.1186/s13256-021-02781-x.

32.

Mori Y, Kobayashi T, Kida Y, Oda K, Shibamoto Y, Yoshida J. Stereotactic radiosurgery as a salvage treatment for recurrent skull base adenoid cystic carcinoma. Stereotact Funct Neurosurg. 2005;83(5-6):202–7. https://doi.org/10.1159/000091084.CrossRefPubMed

33.

Iguchi T, Hiraki T, Gobara H, Fujiwara H, Matsui Y, Toyooka S, et al. Radiofrequency ablation of lung metastases from adenoid cystic carcinoma of the head and neck: retrospective evaluation of nine patients. J Vasc Interv Radiol. 2015;26(5):703–8. https://doi.org/10.1016/j.jvir.2014.11.040.CrossRefPubMed

34.

Leppelmann KS, Levesque VM, Bunck AC, Cahalane AM, Lanuti M, Silverman SG, et al. Outcomes following percutaneous microwave and cryoablation of lung metastases from adenoid cystic carcinoma of the head and neck: a bi-institutional retrospective cohort study. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09714-4.

35.

Laurie SA, Ho AL, Fury MG, Sherman E, Pfister DG. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. Lancet Oncol. 2011;12(8):815–24. https://doi.org/10.1016/S1470-2045(10)70245-X.CrossRefPubMed

36.

Schramm VL Jr, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol. 1981;107(12):739–41. https://doi.org/10.1001/archotol.1981.00790480015004.CrossRefPubMed

37.

Dreyfuss AI, Clark JR, Fallon BG, Posner MR, Norris CM Jr, Miller D. Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer. 1987;60(12):2869–72. https://doi.org/10.1002/1097-0142(19871215)60:12<2869::aid-cncr2820601203>3.0.co;2-y.CrossRefPubMed

38.

Belani CP, Eisenberger MA, Gray WC. Preliminary experience with chemotherapy in advanced salivary gland neoplasms. Med Pediatr Oncol. 1988;16(3):197–202. https://doi.org/10.1002/mpo.2950160309.CrossRefPubMed

39.

Creagan ET, Woods JE, Rubin J, Schaid DJ. Cisplatin-based chemotherapy for neoplasms arising from salivary glands and contiguous structures in the head and neck. Cancer. 1988;62(11):2313–9. https://doi.org/10.1002/1097-0142(19881201)62:11<2313::aid-cncr2820621110>3.0.co;2-4.CrossRefPubMed

40.

Licitra L, Cavina R, Grandi C, Palma SD, Guzzo M, Demicheli R, et al. Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase II trial of 22 patients. Ann Oncol. 1996;7(6):640–2. https://doi.org/10.1093/oxfordjournals.annonc.a010684.CrossRefPubMed

41.

Airoldi M, Pedani F, Succo G, Gabriele AM, Ragona R, Marchionatti S, et al. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91(3):541–7. https://doi.org/10.1002/1097-0142(20010201)91:3<541::aid-cncr1032>3.0.co;2-y.CrossRefPubMed

42.

Hong MH, Kim CG, Koh YW, Choi EC, Kim J, Yoon SO, et al. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck. Head Neck. 2018;40(1):55–62. https://doi.org/10.1002/hed.24933.CrossRefPubMed

43.

Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45(7):791–8. https://doi.org/10.1038/ng.2643.CrossRefPubMedPubMedCentral

44.

Frerich CA, Brayer KJ, Painter BM, Kang H, Mitani Y, El-Naggar AK et al. Transcriptomes define distinct subgroups of salivary gland adenoid cystic carcinoma with different driver mutations and outcomes. Oncotarget. 2018;9(7):7341-58. doi:10.18632/oncotarget.23641.

45.

Park S, Nam SJ, Keam B, Kim TM, Jeon YK, Lee SH, et al. Vegf and ki-67 overexpression in predicting poor overall survival in adenoid cystic carcinoma. Cancer Res Treat. 2016;48(2):518–26. https://doi.org/10.4143/crt.2015.093.CrossRefPubMed

46.

Ho AL, Dunn L, Sherman EJ, Fury MG, Baxi SS, Chandramohan R, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27(10):1902–8. https://doi.org/10.1093/annonc/mdw287.CrossRefPubMedPubMedCentral

47.

• Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N et al. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529-37. doi:10.1200/jco.18.01859. This is a phase II study of levantinib in patients with metastatic ACC with promising results in terms of disease control.

48.

• Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, Cavalieri S et al. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life. Cancer. 2020;126(9):1888-94. doi:https://doi.org/10.1002/cncr.32754. This is a phase II study of lenvatinib in patients with metastatic ACC with promising results in terms of disease control.

49.

• Zhu G, Zhang L, Dou S, Li R, Li J, Ye L et al. Apatinib in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a single-arm, phase II prospective study. Ther Adv Med Oncol. 2021;13:17588359211013626. doi:10.1177/17588359211013626. This is phase II trial of apatinib for R/M ACC that showed the highest ORR (46.2%) seen in ACC thus far. A randomized study is currently ongoing to confirm results.

50.

Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14(9):2717–25. https://doi.org/10.1158/1078-0432.Ccr-07-4575.CrossRefPubMed

51.

Ghosal N, Mais K, Shenjere P, Julyan P, Hastings D, Ward T, et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg. 2011;49(7):510–5. https://doi.org/10.1016/j.bjoms.2010.09.013.CrossRefPubMed

52.

Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158–65. https://doi.org/10.1016/j.ejca.2016.09.022.CrossRefPubMed

53.

Guigay J, Fayette J, Even C, Cupissol D, Rolland F, Peyrade F et al. PACSA: phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC). J Clin Oncol. 2016;34(15_suppl):6086-. doi:10.1200/JCO.2016.34.15_suppl.6086.

54.

Ho AL, Sherman EJ, Baxi SS, Haque S, Ni A, Antonescu CR et al. Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2016;34(15_suppl):6096-. doi:10.1200/JCO.2016.34.15_suppl.6096.

55.

Boxtel WV, Uijen M, Driessen C, Pegge S, Willems SM, Jonker M et al. A phase II study on the efficacy and toxicity of cabozantinib in recurrent/metastatic salivary gland cancer patients. J Clin Oncol. 2020;38(15_suppl):6529-. doi:10.1200/JCO.2020.38.15_suppl.6529.

56.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, et al. Activating notch1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors. J Clin Oncol. 2017;35(3):352–60. https://doi.org/10.1200/jco.2016.67.5264.CrossRefPubMed

57.

Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, et al. Safety and clinical activity of the notch inhibitor, crenigacestat (ly3039478), in an open-label phase i trial expansion cohort of advanced or metastatic adenoid cystic carcinoma. Invest New Drugs. 2020;38(2):402–9. https://doi.org/10.1007/s10637-019-00739-x.CrossRefPubMed

58.

Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018;29(7):1561–8. https://doi.org/10.1093/annonc/mdy171.CrossRefPubMed

59.

R. Ferrarotto LJW, J. Muzaffar, C.P. Rodriguez, B. Xia, C.A. Perez, D.W. Bowles, E. Winquist, S.J. Hotte, R. Metcalf, C. Even, G.B. Gordon, G. Gordon, A. Ho. ACCURACY a phase II trial of al101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring notch activating mutations (notchmut). Annals of Oncology 2020;31(S599-S628). doi:10.1016/annonc/annonc277.

60.

A.L. Ho DWB, C. Even, D. Hao, H. Kang, R. Metcalf, J. Muzaffar, M. Oliva, C.A. Perez, A. Popovtzer, C.P. Rodriguez, S.M. Stemmer, C.M. Van Herpen, E. Winquist, L.J. Wirth, F.P. Worden, B. Xia, G. Gordon, G.B. Gordon, R. Ferrarotto. 904p - ACCURACY: a phase II trial of al101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring notch activating mutations (notchmut): results of 6-mg cohort. Ann Oncol. 2021;32:S786-S817. doi:10.1016/annonc/annonc704.

61.

Weber D, Lehal R, Frismantas V, Bourquin JP, Bauer M, Murone M et al. 66p - pharmacological activity of CB-103: an oral pan-NOTCH inhibitor targeting the NOTCH transcription complex. Ann Oncol. 2018;29:iii14. doi:https://doi.org/10.1093/annonc/mdy047.015.

62.

Miranda EL, Stathis A, Hess D, Racca F, Quon D, Rodon J et al. Phase 1 study of CB-103, a novel first-in-class inhibitor of the CSL-NICD gene transcription factor complex in human cancers. J Clin Oncol. 2021;39(15_suppl):3020-. doi:10.1200/JCO.2021.39.15_suppl.3020.

63.

Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a national cancer institute organ dysfunction working group study. J Clin Oncol. 2010;28(29):4507–12. https://doi.org/10.1200/jco.2010.30.2307.CrossRefPubMedPubMedCentral

64.

Goncalves PH, Heilbrun LK, Barrett MT, Kummar S, Hansen AR, Siu LL et al. A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget. 2017;8(20):32918-29. doi:10.18632/oncotarget.16464.

65.

Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26(4):837–45. https://doi.org/10.1158/1078-0432.CCR-19-2214.CrossRefPubMed

66.

Chaturvedi NK, Mahapatra S, Kesherwani V, Kling MJ, Shukla M, Ray S, et al. Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) medulloblastoma. BMC Cancer. 2019;19(1):1056. https://doi.org/10.1186/s12885-019-6291-z.CrossRefPubMedPubMedCentral

67.

Xu P, Dan G, Chen B, Zhao Q, Zhou R-F, Ouyang J. C-MYC-driven and PRMT5-dependent regulation of multiple myeloma cell proliferation through TNRC6B gene. Blood. 2019;134(Supplement_1):5520-. doi:10.1182/blood-2019-125027.

68.

Bonnal SC, López-Oreja I, Valcárcel J. Roles and mechanisms of alternative splicing in cancer - implications for care. Nat Rev Clin Oncol. 2020;17(8):457–74. https://doi.org/10.1038/s41571-020-0350-x.CrossRefPubMed

69.

Siu LL, Rasco DW, Vinay SP, Romano PM, Menis J, Opdam FL, et al. Meteor-1: a phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours. Ann Oncol. 2019;30:v159.CrossRef

70.

Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2001;17:615–75. https://doi.org/10.1146/annurev.cellbio.17.1.615.CrossRefPubMed

71.

Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, et al. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123(7):2965–8. https://doi.org/10.1172/jci67201.CrossRefPubMedPubMedCentral

72.

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, et al. Immune profiling of adenoid cystic carcinoma: PD-L2 expression and associations with tumor-infiltrating lymphocytes. Cancer Immunology Research. 2016;4(8):679–87. https://doi.org/10.1158/2326-6066.Cir-16-0031.CrossRefPubMed

73.

Kim DW, Oh DY, Shin SH, Kang JH, Cho BC, Chung JS, et al. A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma. BMC Cancer. 2014;14:795. https://doi.org/10.1186/1471-2407-14-795.CrossRefPubMedPubMedCentral

74.

Ho AL, Foster NR, Meyers JP, Vasudeva SD, Katabi N, Antonescu CR et al. Alliance A091104: a phase II trial of MK-2206 in patients (pts) with progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2015;33(15_suppl):6039-. doi:10.1200/jco.2015.33.15_suppl.6039.

75.

Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, et al. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res. 2010;16(19):4722–31. https://doi.org/10.1158/1078-0432.CCR-10-0463.CrossRefPubMedPubMedCentral

76.

Brill LB, Kanner WA, Fehr A, Andrén Y, Moskaluk CA, Löning T, et al. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol. 2011;24(9):1169–76. https://doi.org/10.1038/modpathol.2011.86.CrossRefPubMed

77.

Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A. 2009;106(44):18740–4. https://doi.org/10.1073/pnas.0909114106.CrossRefPubMedPubMedCentral

78.

Gao R, Cao C, Zhang M, Lopez MC, Yan Y, Chen Z et al. A unifying gene signature for adenoid cystic cancer identifies parallel MYB-dependent and MYB-independent therapeutic targets. Oncotarget. 2014;5(24):12528-42. doi:10.18632/oncotarget.2985.

79.

Fujii K, Murase T, Beppu S, Saida K, Takino H, Masaki A, et al. MYB, MYBL1, MYBL2 and NFIB gene alterations and myc overexpression in salivary gland adenoid cystic carcinoma. Histopathology. 2017;71(5):823–34. https://doi.org/10.1111/his.13281.CrossRefPubMed

80.

Hanna GJ, Oneill A, Cutler JM, Flynn M, Vijaykumar T, Clark JR, et al. A phase II trial of all-trans retinoic acid (atra) in advanced adenoid cystic carcinoma. Oral Oncol. 2021;119:105366. https://doi.org/10.1016/j.oraloncology.2021.105366.CrossRefPubMed

81.

Vered M, Braunstein E, Buchner A. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck. 2002;24(7):632–6. https://doi.org/10.1002/hed.10104.CrossRefPubMed

82.

Saida K, Murase T, Ito M, Fujii K, Takino H, Masaki A et al. Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma. Oncotarget. 2018;9(24):17043-55. doi:10.18632/oncotarget.24818.

83.

Locati LD, Bossi P, Perrone F, Potepan P, Crippa F, Mariani L, et al. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol. 2009;45(7):574–8. https://doi.org/10.1016/j.oraloncology.2008.07.010.CrossRefPubMed

84.

Agulnik M, Cohen EWE, Cohen RB, Chen EX, Vokes EE, Hotte SJ, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non–adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol. 2007;25(25):3978–84. https://doi.org/10.1200/jco.2007.11.8612.CrossRefPubMed

85.

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, et al. Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015;37(5):644–9. https://doi.org/10.1002/hed.23647.CrossRefPubMedPubMedCentral

86.

Konopleva M, Martinelli G, Daver N, Papayannidis C, Wei A, Higgins B, et al. MDM2 inhibition: an important step forward in cancer therapy. Leukemia. 2020;34(11):2858–74. https://doi.org/10.1038/s41375-020-0949-z.CrossRefPubMed

87.

de Lima MdDM, Marques YMFS, de Melo Alves S, Freitas VM, Soares FA, de Araújo VC et al. MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol. 2009;33(2):142-6. doi:https://doi.org/10.1016/j.canep.2009.04.016.

88.

Mantesso A, Loducca SVL, Bendit I, Garicochea B, Nunes FD, De Araújo VC. Mdm2 mRNA expression in salivary gland tumour cell lines. J Oral Pathol Med. 2004;33(2):96–101. https://doi.org/10.1111/j.1600-0714.2004.00189.x.CrossRefPubMed

89.

Nör F, Warner KA, Zhang Z, Acasigua GA, Pearson AT, Kerk SA, et al. Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas. Clin Cancer Res. 2017;23(4):1036–48. https://doi.org/10.1158/1078-0432.Ccr-16-1235.CrossRefPubMed

90.

Zhang X, Wen X, Yang C, Zeng S, Men L, Wang H et al. A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. J Clin Oncol. 2019;37(15_suppl):3124-. doi:10.1200/JCO.2019.37.15_suppl.3124.

91.

van Boxtel W, Lutje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, et al. (68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;10(5):2273–83. https://doi.org/10.7150/thno.38501.CrossRefPubMedPubMedCentral

92.

• Linxweiler M, Kuo F, Katabi N, Lee M, Nadeem Z, Dalin MG et al. The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res. 2020;26(12):2859-70. doi:10.1158/1078-0432.Ccr-19-3758. A comprehensive study of the tumor immune microenvironment and neoantigen landscape of salivary gland carcinomas, including ACC.

93.

Mosconi C, de Arruda JAA, de Farias ACR, Oliveira GAQ, de Paula HM, Fonseca FP, et al. Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncol. 2019;88:95–101. https://doi.org/10.1016/j.oraloncology.2018.11.028.CrossRefPubMed

94.

Schoenfeld JD, Mahmood U, Chen Y-H, Mak RH, Lorch JH, Hanna GJ et al. A randomized phase II study of pembrolizumab with or without radiation in patients with recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(15_suppl):6082-. doi:10.1200/JCO.2019.37.15_suppl.6082.

95.

• Tchekmedyian V, Sherman EJ, Dunn L, Fetten JV, Michel LS, Kriplani A et al. A phase II trial cohort of nivolumab plus ipilimumab in patients (pts) with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). J Clin Oncol. 2019;37(15_suppl):6084-. doi:10.1200/JCO.2019.37.15_suppl.6084. This is a phase II study of nivolumab with or without ipilimumab for patients with advanced ACC. This study showed a limited anti-tumor activity of these agents for ACC treatment.

96.

Fayette J, Even C, Digue L, Geoffrois L, Rolland F, Cupissol D et al. Niscahn: a phase II, multicenter nonrandomized trial aiming at evaluating nivolumab (N) in two cohorts of patients (pts) with recurrent/metastatic (R/M) salivary gland carcinoma of the head and neck (SGCHN), on behalf of the unicancer head & neck group. J Clin Oncol. 2019;37(15_suppl):6083-. doi:10.1200/JCO.2019.37.15_suppl.6083.

97.

Keam B, Kim SB, Shin SH, Cho BC, Lee KW, Kim MK, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 2015;121(15):2612–7. https://doi.org/10.1002/cncr.29401.CrossRefPubMed

98.

Dillon PM, Petroni GR, Horton BJ, Moskaluk CA, Fracasso PM, Douvas MG, et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23(15):4138–45. https://doi.org/10.1158/1078-0432.Ccr-16-2942.CrossRefPubMedPubMedCentral

99.

Thomson DJ, Silva P, Denton K, Bonington S, Mak SK, Swindell R, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015;37(2):182–7. https://doi.org/10.1002/hed.23577.CrossRefPubMed

100.

Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23(6):1562–70. https://doi.org/10.1093/annonc/mdr522.CrossRefPubMed

Title: Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma
Authors: Luana Guimaraes de Sousa
Felippe Lazar Neto
Jessica Lin
Renata Ferrarotto
Publication date: 01-05-2022
Publisher: Springer US
Keywords: Systemic Therapy
Targeted Therapy
Published in: Current Oncology Reports / Issue 5/2022
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-022-01233-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 5/2022

Clinicopathological Review of Micropapillary Urothelial Carcinoma

Management of Upper Tract Urothelial Carcinoma

Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment

Treatment Strategy for Elderly Patients with Soft Tissue Sarcoma

Emerging Studies of Melanoma Brain Metastasis

The Value Proposition of Observation Medicine in Managing Acute Oncologic Pain

Keynote webinar | Spotlight on antibody–drug conjugates in cancer